



(51) International Patent Classification:

A61K 9/16 (2006.01) A61K 47/30 (2006.01)
A61K 47/48 (2006.01)

(21) International Application Number:

PCT/KR2012/006206

(22) International Filing Date:

3 August 2012 (03.08.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2011-0077534 3 August 2011 (03.08.2011) KR

(71) Applicant (for all designated States except US): **HAN-WHA CHEMICAL CORPORATION** [KR/KR]; 1, Janggyo-dong, Jung-gu, Seoul 100-220 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIM, Eung Gyu** [KR/KR]; #116-601, Malgeunachim Apt., Nae-dong, Seo-gu, Daejeon 302-981 (KR). **JEON, Bong-Sik** [KR/KR]; #101-1311, Ganapalosbil, Jijok-dong, Yuseong-gu, Daejeon 305-330 (KR). **KWON, Eun Byul** [KR/KR]; #109-505, Daelim Dure Apt., Sinseong-dong, Yuseong-gu, Daejeon 305-720 (KR). **PARK, Ju Young** [KR/KR]; #110-204, Daelim Dure Apt., Sinseong-dong, Yuseong-gu, Daejeon 305-720 (KR). **MYEONG, Wan Jae** [KR/KR]; #908-201, Daedeok TechnoValley 9-danji Apt., Gwanpyeong-dong, Yuseong-gu, Daejeon 305-739 (KR).

(74) Agents: **KWON, Oh-Sig** et al.; 401, Joeeun Officetel, 138 Dunsanjung-ro, Seo-gu, Daejeon 302-120 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: HYDROPHILIC NANOPARTICLES SURFACE-MODIFIED WITH MONOSACCHARIDE PHOSPHATE OR MONOSACCHARIDE PHOSPHATE DERIVATIVES, ITS COLLOIDAL SOLUTION AND USE THEREOF

[Figure 3]



(57) Abstract: Disclosed are a composition including hydrophilic nanoparticles that have a monosaccharide-phosphate or a derivative thereof adhered to the surface thereof, a colloidal solution of the composition dispersed in water, and a magnetic resonance imaging contrast agent including the colloidal solution. According to the present invention, nanoparticles having biocompatibility and excellent water-dispersibility can be prepared by modifying the surface of inorganic nanoparticles. The prepared nanoparticles may be effectively used in a variety of applications including, for example, in vivo imaging applications, such as an MRI contrast agent, nano-electronic convergence technologies such as a quantum dot light emitting device, biomedical applications such as hyperthermia, or the like. Moreover, compared to existing nanoparticles dispersed by a dispersion stabilizer known in the art, excellent dispersion stability and a relatively small hydrodynamic diameter may be attained.

Description

Title of Invention: HYDROPHILIC NANOPARTICLES SURFACE-MODIFIED WITH MONOSACCHARIDE PHOSPHATE OR MONOSACCHARIDE PHOSPHATE DERIVATIVES, ITS COLLOIDAL SOLUTION AND USE THEREOF

Technical Field

- [1] The following disclosure relates to a composition including hydrophilic nanoparticles having a monosaccharide-phosphate or its derivative bonded on the surface thereof, a colloidal solution thereof and its use. More particularly, a composition including inorganic nanoparticles surface-modified with a monosaccharide-phosphate or its derivative, a colloidal solution prepared by dispersing the composition in water, and a magnetic resonance imaging contrast agent including the same.

Background Art

- [2] Nanoparticles are used in a broad range of applications such as *in vivo* imaging technology, medical applications, gene transfer, drug delivery, diagnosis and treatment of diseases, etc. Specifically, nanoparticles are widely used in a variety of biomedical applications including, for example, a magnetic resonance imaging (MRI) contrast agent, cellular level therapy, hyperthermia, drug delivery, nucleic acid isolation, or the like, thereby increasing importance thereof.
- [3] The most important requirement for the application of nanoparticles in biomedical applications is primarily to ensure high quality nanoparticles and, in addition, to allow nanoparticles to have water-dispersion stability to stably maintain the nanoparticles *in vivo*. Here, a high quality nanoparticle may mean a nanoparticle with features of; (i) uniformity of particle size, (ii) easy control of particle size, (iii) excellent particle crystallinity, etc.
- [4] In order to accomplish satisfactory results *in vitro* and *in vivo* by applying such high quality nanoparticles to a human body and bioscience technologies, it is necessary to select a nanoparticle suitable to the characteristics of a specific application and, above all, a skill to treat nanoparticles with a bio-compatible material having excellent dispersibility.
- [5] Nanoparticles commercially available in the art are mostly synthesized by co-precipitation that controls pH in an aqueous system to precipitate the nanoparticles, or obtained by synthesis in a gas phase. However, nanoparticles generated by the foregoing processes are significantly agglomerated due to the lack of a stabilizer on the surface of the synthesized nanoparticles, and have difficulties in controlling a size of

nanoparticle and preparing nanoparticles with a uniform size.

- [6] A method for synthesis of nanoparticles having a lipophilic surfactant adhered to the surface thereof by thermal decomposition of an inorganic precursor as well as the surfactant in an organic solvent at high temperature has recently been developed. This method has advantages in that size and shape of nanoparticles are preferably controlled, the synthesized nanoparticles show high uniformity in size and excellent crystallinity without agglomeration. However, the synthesized nanoparticles also have disadvantages in that, since a surfactant having hydrophobic properties is adhered the surface of the synthesized nanoparticles, these nanoparticles are not dispersed in water and are problematic when used *in vivo*. Therefore, in order to use such prepared inorganic nanoparticles *in vivo*, surface modification into a hydrophilic state is necessary. There are generally three kinds of methods for surface modification of hydrophobic nanoparticles into a hydrophilic state.
- [7] A first one is a ligand exchange method, wherein excess of ligands having functional groups bondable to the surface of nanoparticles are introduced to allow the ligands to be bonded at a site where the surfactant was detached.
- [8] A second one is an encapsulation method, wherein amphiphilic ligands are introduced to nanoparticles, in order to allow a hydrophobic portion of the amphiphilic ligand facing a surfactant part of the nanoparticle while a hydrophilic portion thereof is exposed to the outside, thus becoming hydrophilic. However, this method requires complicated experimental conditions since separate particles are surrounded with an amphiphilic material, and causes problems for mass production.
- [9] A third one is a method of using micelles wherein micelles are prepared in a solvent containing hydrophobic nanoparticles dispersed therein and the nanoparticles are introduced into the micelles. This method is characterized in that several nanoparticles are introduced into one micelle, thus causing a problem in preparing hydrophilic nanoparticles having a small hydrodynamic diameter. Moreover, a problem of causing breakage of micelles due to increase/decrease in a concentration of ions *in vivo* and/or a blood flow rate may be caused.
- [10] Accordingly, numerous studies have currently been executed to develop a novel method for hydrophilization of nanoparticles through ligand exchanging. However, it is important to suitably select a functional group enabling bonding of the ligand to the surface of nanoparticle that is combined with a surfactant. A chargeable functional group can generally bond well to the surface of a nanoparticle and examples thereof may mostly include amines, phosphates, sulfates, carboxylate, etc.
- [11] In general, hydrophilized nanoparticles may have dispersion stability in water depending upon characteristics of hydrophilic materials. In the case of a single molecule, nanoparticles are not cohered due to repulsion caused by charge of

molecules, instead, maintain water-dispersibility. However, the nanoparticles may be cohered with a change of pH, thus having inferior dispersion stability *in vivo*.

Therefore, hydrophilization of nanoparticles including surface modification using ligands with relatively large molecular weight and utilizing van-der-Waals force has currently been studied. However, the nanoparticles hydrophilized by ligands having a large molecular weight entail problems such as a large hydrodynamic diameter and difficulties in ligand exchanging when the molecular weight is increased.

[12] Moreover, preparation of bio-compatible ligands needs a complicated manufacturing process and entails a difficulty in mass production thereof.

[13] In recent years, a water dispersion method of nanoparticles using a polymer comprising of phosphine oxide and polyethyleneglycol (PEG) has been disclosed in, for example, "Versatile PEG-derivatized Phosphine Oxide Ligands for Water-Dispersible Metal Oxide Nanocrystals," by Hyon Bin Na, In Su Lee, Heon Jin Seo, Yong Il Park, Jung Hee LEE, Sang Wook Kim and Taeghwan Hyeon (Chem. Comm., 2007, 5167). Alternatively, a method that includes reacting methoxy polyethyleneglycol with phosphoryl chloride (POCl_3) to synthesize PO-PEG ligand, ligand exchanging the synthesized PO-PEG ligand with nanoparticles in an organic solvent and dispersing the same in water, has been disclosed. Although this method adopts a relatively simple manufacturing process, phosphoryl chloride (POCl_3) readily contacts oxygen to be oxidized in the preparation of ligands, thus causing difficulties in processing such as a requirement for synthesis in an inert atmosphere such as argon or nitrogen. Furthermore, one to three polyethyleneglycols are bonded to a phosphoryl group in the preparation of ligands, thus having a problem in preparing reproducible ligands.

Disclosure of Invention

Technical Problem

[14] Therefore, as a result of intensive and extensive efforts to overcome the above problems in the related art, the present inventors have found a dispersion stabilizer capable of modifying the surface of nanoparticles into a hydrophilic state to enable dispersion of the nanoparticles in an aqueous system, and have discovered that a composition of hydrophilic nanoparticles including the foregoing dispersion stabilizer adhered thereto may be effectively used in biomedical applications.

[15] Accordingly, an object of the present invention is to provide a composition of hydrophilic nanoparticles containing a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the nanoparticles.

[16] Another object of the present invention is to provide a monosaccharide-phosphate derivative formed by combining a monosaccharide-phosphate with a

polyethyleneglycol polymer or alcohol having an amine group bonded thereto and, in addition, a composition of hydrophilic nanoparticles containing the above derivative adhered to the surface thereof.

[17] Another object of the present invention is to provide a colloidal solution prepared by dispersing the above composition in water, wherein the composition includes hydrophilic nanoparticles containing a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the nanoparticles, a contrast agent including the above colloidal solution and, in addition, an imaging method including *in vivo* injection of the contrast agent.

[18] A still further object of the present invention is to provide a process for modifying the surface of lipophilic nanoparticles with hydrophilic nanoparticles, by contacting a solution, which includes a monosaccharide-phosphate or a monosaccharide-phosphate derivative dispersed in water, with the lipophilic nanoparticles in a polar organic solvent.

Solution to Problem


[19] In order to accomplish the above objects, according to one general aspect of the present invention, a composition including nanoparticles that are surface-modified, in turn being dispersed and stabilized, using a monosaccharide-phosphate or its derivative to enable inorganic nanoparticles to be biocompatible and have excellent water-dispersibility, colloidal solution including the same, and a contrast agent including the colloidal solution.

[20] Hereinafter, the present invention will be described in more detail.

[21] The monosaccharide-phosphate used herein may have a structure represented by formula 1:

[22] [Formula 1]

[23]




[24] In Formula 1, a phosphate group is bonded with one monosaccharide and such monosaccharide used in the present invention may include a monosaccharide having two to nine carbon atoms. Practical examples thereof may include dihydroxy acetone, glyceraldehydes, erythrulose, erythrose, threose, ribulose, xylulose, ribose, arabinose, xylose, lyxose, deoxyribose, pricose, fructose, sorbose, tagatose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, fucose, fuculose, rhamnose, sedoheptulose, neuraminic acid, etc., without being particularly limited thereto.

[25] According to the present invention, a monosaccharide-phosphate is preferably glucose 6-phosphate, fructose 6-phosphate or mannose 6-phosphate.

[26] According to the present invention, the monosaccharide-phosphate derivative has a structure represented by Formula 2:

[27] [Formula 2]

[28]



[29] In Formula 2,

[30] X_1 is a monosaccharide,

[31] X_2 is OH, aminoalcohol or polyethyleneglycol, and X_3 is OH.

[32] Aminoalcohol is preferably one or two or more selected from ethanolamine, heptaminol, isoetharine, norepinephrine, propanolamine and sphingosine.

[33] Polyethyleneglycol may have amine group at one end or both ends thereof and a molecular weight of 300 to 5,000.

[34] According to the present invention, the nanoparticle may be one or two or more selected from a group consisting of metal, metal chalcogenide, metal oxide, magnetic materials, magnetic alloys, semiconductor materials and multi-component hybrid structures.

[35] According to the present invention, metal may be selected from a group consisting of Pd, Pt, Au, Cu and Ag, metal calcogenide may be selected from M_xE_y ($\text{M}=\text{Ti}, \text{V}, \text{Cr}, \text{Mn}, \text{Fe}, \text{Co}, \text{Ni}, \text{Cu}, \text{Zr}, \text{Mo}, \text{Ru}, \text{Rh}, \text{Ag}, \text{W}, \text{Re}, \text{Ta}, \text{Hf}$ and Zn ; $\text{E}=\text{O}, \text{S}$ or Se ; $0 < x \leq 3$; $0 < y \leq 5$), metal oxide may be selected from titanium oxide, vanadium oxide, chromium oxide, manganese oxide, iron oxide, cobalt oxide, nickel oxide, copper oxide, zirconium oxide, molybdenum oxide, ruthenium oxide, rhodium oxide, silver oxide, tungsten oxide, rhenium oxide, tantalum oxide, hafnium oxide and zinc oxide. More preferably, metal oxide is selected from FeO , Fe_3O_4 (magnetite), $\alpha\text{-Fe}_2\text{O}_3$, $\beta\text{-Fe}_2\text{O}_3$, $\gamma\text{-Fe}_2\text{O}_3$ (maghemite), $\epsilon\text{-Fe}_2\text{O}_3$, $\text{Fe}(\text{OH})_2$, $\text{Fe}(\text{OH})_3$, $\alpha\text{-FeOOH}$, $\beta\text{-FeOOH}$, $\gamma\text{-FeOOH}$, $\delta\text{-FeOOH}$, $\text{Fe}_5\text{HO}_8 \cdot 4\text{H}_2\text{O}$, $5\text{Fe}_2\text{O}_3 \cdot 9\text{H}_2\text{O}$, $\text{FeOOH} \cdot 4\text{H}_2\text{O}$, $\text{Fe}_8\text{O}_8(\text{OH})_6(\text{SO}) \cdot n\text{H}_2\text{O}$, $\text{Fe}^{3+}_{16}\text{O}_{16}(\text{OH} \cdot \text{SO}_4)_{12-13} \cdot 10-12\text{H}_2\text{O}$ and a mixture of Fe_3O_4 (magnetite) and $\gamma\text{-Fe}_2\text{O}_3$ (maghemite). Preferably, the magnetic material is selected from a group consisting of Co, Mn, Fe, Ni, Gd, $\text{MM}'_2\text{O}_4$, M_xO_y (M or $\text{M}' = \text{Co}, \text{Fe}, \text{Ni}, \text{Mn}, \text{Zn}, \text{Gd}, \text{Cr}$; $0 < x \leq 3$; $0 < y \leq 5$), while the magnetic alloys may be selected from a group consisting of CoCu, CoPt, FePt, CoSm, NiFe and NiFeCo. The semiconductor materials may be selected from a group consisting of: semiconductor comprising of elements selected from Groups 2 and 6, re-

spectively; semiconductor comprising of elements selected from Groups 3 and 5, respectively; semiconductor comprising of Group 4 element; semiconductor comprising of elements selected from Groups 4 and 6, respectively; and semiconductor comprising of elements selected from Groups 5 and 6, respectively. The multi-component hybrid structure may include at least two components selected from a group consisting of metal, metal chalcogenide, magnetic materials, magnetic alloys and semiconductor materials and, in addition, a material having a core-shell or heterojunction structure.

[36] The surface-modified hydrophilic nanoparticle may have a size of 1 nm to 200 nm.

[37] The present invention also provides a colloidal solution prepared by dispersing a composition in water, wherein the composition includes hydrophilic nanoparticles having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the nanoparticles, a contrast agent including the above colloidal solution and, in addition, an imaging method including *in vivo* injection of the contrast agent.

[38] The present invention also provides a composition that includes iron oxide nanoparticles having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the nanoparticles. The monosaccharide-phosphate is preferably selected from glucose 6-phosphate, fructose 6-phosphate and mannose 6-phosphate. The monosaccharide-phosphate derivative may comprise a monosaccharide-phosphate, of which a phosphate group is bonded with aminoalcohol or polyethyleneglycol and, more preferably, with a specific polyethyleneglycol having amine groups at one end or both ends thereof and a molecular weight of 300 to 50,000. Iron oxide may include a variety of iron oxides and, among them, preferably includes magnetite (Fe_3O_4), maghemite ($\gamma\text{-Fe}_2\text{O}_3$) or a mixture thereof. The present invention may provide a colloidal solution prepared by dispersing a composition, which includes iron oxide nanoparticles having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the nanoparticles, in water. By adding any of injectable additives, for example, a sodium chloride solution, a solvent such as a dextrose injection, a pH controlling buffer, an isotonic agent to control osmotic pressure to match with blood pressure, an analgesic agent such as glucose, or the like, to the above colloidal solution, to prepare a contrast agent injectable *in vivo* and, in addition, an imaging method including *in vivo* injection of the contrast agent.

[39] Further, the present invention may provide colloids prepared by dispersing a composition, which includes hydrophilic iron oxide having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the iron oxide, in water, wherein: (i) the iron oxide is magnetite (Fe_3O_4), maghemite ($\gamma\text{-Fe}_2\text{O}_3$) or a mixture thereof; and (ii) a difference between a number mean hydrodynamic diameter of a hydrophilic composition and a core diameter of an iron oxide core particle is 6 nm

or less, as well as a magnetic resonance imaging (MRI) contrast agent including the above colloids.

[40] In addition, the present invention may provide colloids prepared by dispersing a composition, which includes hydrophilic iron oxide having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the iron oxide, in water, wherein: (i) the monosaccharide-phosphate or monosaccharide-phosphate derivative is glucose 6-phosphate or the same having ethanolamine or polyethyleneglycol bonded thereto; (ii) a size of an iron oxide core ranges from 2 nm to 8 nm; and (iii) a number mean hydrodynamic diameter (measured by a dynamic light scattering (DLS) method) of a hydrophilic composition ranges from 2 nm to 15 nm, as well as MRI T1 contrast agent including the above colloids.

[41] Moreover, the present invention may provide colloids prepared by dispersing a composition, which includes hydrophilic iron oxide having a monosaccharide-phosphate derivative adhered to the surface of the iron oxide, in water, wherein: (i) the monosaccharide-phosphate derivative is glucose 6-phosphate having ethanolamine or polyethyleneglycol bonded thereto; (ii) a size of an iron oxide core ranges from 7 nm to 25 nm; and (iii) a number mean hydrodynamic diameter of a hydrophilic composition (measured by a dynamic light scattering (DLS) method) ranges from 7 nm to 50 nm, as well as MRI T2 contrast agent including the above colloids.

[42] Still further, the present invention provides a surface modification process for modifying the surface of nanoparticles into a hydrophilic state by contacting a solution, which includes a monosaccharide-phosphate or a monosaccharide-phosphate derivative dispersed in water, with a lipophilic nanoparticle solution and a polar organic solvent. Here, the core of the lipophilic nanoparticle may be metal, metal chalcogenide, metal oxide, a magnetic material, a magnetic alloy, a semiconductor material or a multi-component hybrid structure and, preferably, iron oxide. The polar organic solvent may be tetrahydrofuran, iso-propanol, n-propanol, methanol, ethanol, dioxane, dimethyl sulfoxide, dimethylformamide, acetonitrile, acetone, acetic acid.

Advantageous Effects of Invention

[43] According to the present invention, the surface of inorganic nanoparticles may be modified into a hydrophilic state using a monosaccharide-phosphate or a monosaccharide-phosphate derivative, thereby easily producing a composition of nanoparticles, which are biocompatible and have excellent water-dispersibility, as well as colloids thereof. Such prepared nanoparticle composition may be effectively used in a variety of applications including, for example: *in vivo* imaging applications such as an MRI contrast agent, computer tomography (CT) contrast agent, etc.; nano-electronic convergence technologies such as a quantum dot light emitting device; biomedical ap-

plications such as hyperthermia, or the like. Moreover, compared to a nanoparticle composition dispersed by a dispersion stabilizer known in the art, excellent dispersion stability and a relatively small hydrodynamic diameter may be attained.

Brief Description of Drawings

- [44] Figure 1 is a transmission electron microscopy (TEM) image showing iron oxide nanoparticles having oleic acid adhered to the surface with a size of 3 nm, which are dispersed in n-Hexane solvent;
- [45] Figure 2 is a TEM image showing iron oxide nanoparticles with a size of 3 nm dispersed in water according to a method in Example 1;
- [46] Figure 3 illustrates measured results of the hydrodynamic diameter of iron oxide nanoparticles dispersed in water according to methods in Examples 1, 2 and 3, wherein (1) shows nanoparticles obtained by hydrophilization of iron oxide nanoparticles having a size of 3 nm with glucose 6-phosphate, thus having a hydrodynamic diameter of 3.8 nm; (2) shows nanoparticles obtained by hydrophilization of iron oxide nanoparticles having a size of 7 nm with mannose 6-phosphate, thus having a hydrodynamic diameter of 8.7 nm; and (3) shows nanoparticles obtained by hydrophilization of iron oxide nanoparticles having a size of 10 nm with fructose 6-phosphate, thus having a hydrodynamic diameter of 11.3 nm;
- [47] Figure 4 is *in vivo* angiographic image of a rat in Example 7-1;
- [48] Figure 5 illustrates a signal intensity of *in vivo* angiographic image of the rat in Example 7-1 in a signal to noise ratio;
- [49] Figure 6 is *in vivo* angiographic image of a rat in Example 8-1;
- [50] Figure 7 illustrates a signal intensity of *in vivo* angiographic image of the rat in Example 8-1 in a signal to noise ratio, specifically, signal intensities of the right atrium, the inferior vena cava (IVC), the aorta, etc.;
- [51] Figure 8 is *in vivo* angiographic image of a rat in Example 8-2;
- [52] Figure 9 illustrates a signal intensity of *in vivo* angiographic image of the rat in Example 8-2 in a signal to noise ratio, specifically, signal intensities of the right atrium, the inferior vena cava (IVC), the aorta, etc.;
- [53] Figure 10 is *in vivo* MRI lymph node contrast image of a mouse in Example 8-3, wherein images before injection (PRE) and 1 day after injection (1 Day) are included, and the image at the top end indicates a brachial lymph node of the mouse while the image at the bottom end indicates an inguinal lymph node of the mouse;
- [54] Figure 11 illustrates a signal intensity of *in vivo* lymph node image of the mouse in Example 8-3 in a signal to noise ratio, specially, shows a variation in signal intensities of brachial and inguinal lymph nodes;
- [55] Figure 12 is *in vivo* MRI lymph node contrast image of a mouse in Example 9,

wherein images before injection (PRE) and 1 day after injection (1 Day) are included, and the image at the upper side indicates a brachial lymph node of the mouse while the image at the lower side indicates an inguinal lymph node of the mouse;

[56] Figure 13 illustrates a signal intensity of *in vivo* lymph image of the mouse in Example 9 in a signal to noise ratio, specially, shows a variation in signal intensities of brachial and inguinal lymph nodes; and

[57] Figure 14 illustrates MTT assay results of Example 11, wherein (A) 10 nm iron oxide nanoparticles stabilized by glucose 6-phosphate, (B) 10 nm iron oxide nanoparticles stabilized by glucose 6-phosphate-PEG derivatives, and (C) 3 nm iron oxide nanoparticles stabilized by glucose 6-phosphate-aminoalcohol.

Mode for the Invention

[58] The advantages, features and aspects of the present invention will become apparent from the following description of the embodiments with reference to the accompanying drawings, which is set forth hereinafter. The technical spirit of the present invention may be easily embodied by those having ordinary knowledge in the art to which the present invention pertains. In addition, technical and/or scientific terminologies used in the detailed description herein have meanings generally understood by those skilled in the related art, to which the present invention pertains, unless otherwise stated. In the following description and the accompanying drawings, a detailed description of technical configurations and/or functions well known in the art will be omitted for brevity without undesirably making the essentials of the present invention unclear.

[59] The present invention provides a composition of nanoparticles having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface thereof.

[60] The monosaccharide-phosphate used herein may be in any form of glucose 6-phosphate, fructose 6-phosphate or mannose 6-phosphate, and may be dispersed in water. The monosaccharide-phosphate derivative used herein may be monosaccharide-phosphate-polyethyleneglycol comprising glucose 6-phosphate, fructose 6-phosphate or mannose 6-phosphate, of which a phosphate group is bonded with a polyethyleneglycol-based biocompatible polymer affinitive to an aqueous medium, and/or monosaccharide-phosphate-aminoalcohol combined with alcohol having an amine group bonded thereto.

[61] A structure of a monosaccharide-phosphate may be represented by Formula 1:

[62] [Formula 1]

[63]



[64]

In Formula 1, a phosphate group is bonded with one monosaccharide and such monosaccharide used in the present invention may include a monosaccharide having two to nine carbon atoms. Practical examples thereof may include dihydroxy acetone, glyceraldehydes, erythrulose, erythrose, threose, ribulose, xylulose, ribose, arabinose, xylose, lyxose, deoxyribose, pricose, fructose, sorbose, tagatose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, fucose, fuculose, rhamnose, sedoheptulose, neuraminic acid, etc., without being particularly limited thereto.

[65]

Alternatively, a polysaccharide may be bonded at a site of a monosaccharide and such polysaccharide may include disaccharides, trisaccharides, tetrasaccharides, oligosaccharides and polysaccharides. Practical examples thereof may include sucrose, lactose, maltose, trehalose, turanose, cellobiose, raffinose, melecitose, maltotriose, acarbose, starch, fructo-oligosaccharide, galacto-oligosaccharide, mannan-oligosaccharide, clucan, glycogen, amylose, amylopectin, cellulose, dextrane, maltodextrin, tructane, mannan, galactane, etc., without being particularly limited thereto.


[66]

A structure of monosaccharide phosphate derivative may be represented by Formula 2:

[67]

[Formula 2]

[68]



[69]

In Formula 2, X₁ is monosaccharide, preferably, glucose, fructose or mannose.

[70]

X₂ is OH, aminoalcohol or polyethyleneglycol.

[71]

For aminoalcohol, for example, ethanolamine, heptaminol, isoetharine, norepinephrine, propanolamine and sphingosine.

[72]

Polyethyleneglycol may be (OCH₂CH₂)_nOH, (OCH(CH₃)CO)_nOH or (OCH₂CO)_nOH, and n is an integer ranging from 1 to 1200. Preferably, polyethyleneglycol has amine groups at one end or both ends and a molecular weight of 300 to 50,000. Combination of the derivative to monosaccharide-phosphate may include any reaction to form a covalent bond between two molecules.

- [73] Combination of aminoalcohol may be accomplished using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) and N-hydroxy succinimide (NHS), to form a phosphoramidate bond between a phosphate group and an amine group of aminoalcohol. Combination of polyethyleneglycol may be achieved by covalent bonding ethylene diamine ($C_2H_8N_2$) with a phosphate group through EDC and NHS to prepare a monosaccharide-phosphate ethylenediamine, and then, covalent bonding the prepared one with the polyethyleneglycol having a carboxyl group at one end thereof through EDC and NHS or, otherwise, using EDC and NHS to form a covalent bond between PEG having an amine group at one end thereof and a monosaccharide-phosphate.
- [74] X_3 is OH.
- [75] Among monosaccharide-phosphates, glucose 6-phosphate is a material generated during glycolysis and enriched *in vivo*, thus being biocompatible. Alternatively, other monosaccharide-phosphates and monosaccharide-phosphate derivatives may also be expected to have excellent biocompatibility.
- [76] Nanoparticles may be selected from metal, metal chalcogenide, metal oxide, magnetic materials, magnetic alloys, semiconductor materials and/or multi-component hybrid structures. A nanoparticle may have a lipophilic ligand bonded to the surface thereof. For instance, for iron oxide, nanoparticles synthesized by thermal decomposition may contain an organic material due to oleic acid, an organic material due to a synthesis solvent or an organic material due to a precipitate adhered to the surface of the nanoparticles. The organic material adhered to the surface of the nanoparticles may be mostly removed by a method according to the present invention, thereby resulting in a nanoparticle composition having hydrophilic properties. A diameter of the nanoparticle may range from 1 nm to 200 nm, preferably, 1 nm to 50 nm.
- [77] Metal nanoparticles may be selected from a group consisting of Pd, Pt, Au, Cu and Ag; metal chalcogenide may be selected from $MxEy$ ($M=Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zr, Mo, Ru, Rh, Ag, W, Re, Ta, Hf$ and Zn ; $E=O, S$ or Se ; $0 < x \leq 3$; $0 < y \leq 5$); and metal oxide may be selected from titanium oxide, vanadium oxide, chromium oxide, manganese oxide, iron oxide, cobalt oxide, nickel oxide, copper oxide, zirconium oxide, molybdenum oxide, ruthenium oxide, rhodium oxide, silver oxide, tungsten oxide, rhenium oxide, tantalum oxide, hafnium oxide and zinc oxide. Among metal oxides, practical examples of iron oxide may be selected from FeO , Fe_3O_4 (magnetite), $\alpha-Fe_2O_3$, $\beta-Fe_2O_3$, $\gamma-Fe_2O_3$ (maghemite), $\epsilon-Fe_2O_3$, $Fe(OH)_2$, $Fe(OH)_3$, $\alpha-FeOOH$, $\beta-FeOOH$, $\gamma-FeOOH$, $\delta-FeOOH$, $Fe_3HO_8 \cdot 4H_2O$, $5Fe_2O_9 \cdot 9H_2O$, $FeOOH \cdot 4H_2O$, $Fe_8O_8(OH)_6(SO)_n \cdot nH_2O$, $Fe^{3+}_{16}O_{16}(OH \cdot SO_4)_{12-13} \cdot 10-12H_2O$ or a mixture of Fe_3O_4 (magnetite) and $\gamma-Fe_2O_3$ (maghemite). On the other hand, the magnetic material may be selected from a group consisting of Co, Mn, Fe, Ni, Gd, MM'_2O_4 , M_xO_y (M or $M' = Co, Fe, Ni, Mn,$

Zn, Gd, Cr; $0 < x \leq 3$; $0 < y \leq 5$), while the magnetic alloys may be selected from a group consisting of CoCu, CoPt, FePt, CoSm, NiFe and NiFeCo. The semiconductor materials may be selected from a group consisting of: semiconductor comprising of elements selected from Groups 2 and 6, respectively; semiconductor comprising of elements selected from Groups 3 and 5, respectively; semiconductor comprising of Group 4 element; semiconductor comprising of elements selected from Groups 4 and 6, respectively; and semiconductor comprising of elements selected from Groups 5 and 6, respectively. The multi-component hybrid structure may include at least two components selected from a group consisting of metal, metal chalcogenide, magnetic materials, magnetic alloys and semiconductor materials and, in addition, a material having a core-shell or heterojunction structure.

[78] A method for preparation of a composition, which includes nanoparticles having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface thereof, may include contacting nanoparticles with a solvent and a solution in which the monosaccharide-phosphate or the monosaccharide-phosphate derivative is dissolved. Such monosaccharide-phosphate or monosaccharide-phosphate derivative may be used as an aqueous solution containing the same dissolved in water. Nanoparticles may be hydrophilic or hydrophobic (that is, lipophilic), therefore, be dispersed in water or an organic solvent. In order to appropriately contact a monosaccharide-phosphate or a monosaccharide-phosphate derivative with nanoparticles and a solvent, a water-affinitive solvent, for example, a polar solvent such as tetrahydrofuran, iso-propanol, n-propanol, methanol, ethanol, dioxane, dimethyl sulfoxide, dimethylformamide, acetonitrile, acetone, acetic acid, etc. may be suitably used. It is considered that the material adhered to the surface of nanoparticles by a monosaccharide-phosphate or a monosaccharide-phosphate derivative undergoes exchange (ligand exchange). A part of the monosaccharide or monosaccharide derivative may surround nanoparticles in a micelle form.

[79] The present invention provides a colloidal solution including a composition dispersed in water, wherein the composition includes iron oxide nanoparticles having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface of the nanoparticles. In order to inject the colloidal solution *in vivo*, a variety of injectable additives, for example; a sodium chloride solution, a solvent such as a dextrose injection, a pH controlling buffer, an isotonic agent to control osmotic pressure to match with blood pressure, an analgesic agent such as glucose, or the like, may be added thereto, to prepare a contrast agent. Furthermore, an imaging method including *in vivo* injection of the contrast agent may be provided. Such *in vivo* injection method may include intravenous injection, oral administration, inhalation, etc., and intravenous injection is most preferably used. The imaging method may

include, for example, MRI (magnetic resonance imaging), X-ray, CT, PET, SPECT, etc. and, among them, MRI is most preferably used. Contrast imaging through MRI may include, for example, negative contrast (T2, darkening) and/or positive contrast (T1, brightening). If a size of the used iron oxide and a number mean hydrodynamic diameter of the hydrophilized composition are not more than 5 nm and 15 nm, respectively, positive contrast imaging is preferably used. On the contrary, in the case where the size of the used iron oxide and the number mean hydrodynamic diameter of the hydrophilized composition exceed 5 nm and 15 nm, respectively, negative contrast imaging is more preferable. If it is possible to decrease a thickness of the hydrophilized surface of the iron oxide, a hydrophilized nanoparticle composition having a slightly larger size than a core size of the iron oxide may be obtained. Therefore, the hydrodynamic diameter may be controlled with high precision. In order to improve long term stability of nanoparticles in water, steric hindrance and electrostatic repulsion may be utilized. Surface coating or ligand exchanging with a hydrophilic polymers has been used in the art. But, polymers make the hydrodynamic diameter too thick. When small molecules are attached to the surface of nanoparticle, a hydrodynamic diameter can be reduced. But, long term stability in water is deteriorated and biocompatibility is restricted. Consequently, there is a strong need for enhancing long term stability while decreasing a hydrodynamic diameter of a particle.

[80] The present invention also describes colloids and an MRI contrast agent with long blood retention time including the colloids. The colloids are prepared by dispersing a composition, which includes hydrophilic iron oxide nanoparticle having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface, in water, wherein: (i) the iron oxide is magnetite (Fe_3O_4), maghemite ($\gamma\text{-Fe}_2\text{O}_3$) or a mixture thereof; and (ii) a difference between a number mean hydrodynamic diameter of a hydrophilic composition and a core diameter of iron oxide core particle is 6 nm or less. In the case where the difference in size between the hydrodynamic diameter of the hydrophilic composition and the diameter of the iron oxide core is small, the hydrophilized nanoparticle composition may a larger retention time in blood. Existing MRI contrast agents, i.e., Gd-complex (Magnevist-Bayer Schering Co., Omniscan-GE Healthcare Co.) has a very short BHL of several minutes or less, while an iron oxide-based contrast agent (Feridex-AMAG Co., Resovist-Gayer Schering Co.) is delivered into and distributed in the liver within several tens of minutes by macrophage. Accordingly, there is a strong need for a novel and improved hydrophilization method that extends a blood retention time or BHL(blood half life) by decreasing a hydrodynamic diameter of an iron oxide nanoparticle composition after hydrophilization.

[81] Further, the present invention describes colloids and T1 MRI contrast agent including

the colloids. The Colloids are prepared by dispersing a composition, which includes hydrophilic iron oxide particle having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface, in water, wherein: (i) the monosaccharide-phosphate or monosaccharide-phosphate derivative is selected from glucose 6-phosphate or its derivative having ethanolamine or polyethyleneglycol bonded thereto; (ii) a size of an iron oxide core ranges from 2 nm to 8 nm; and (iii) a number mean hydrodynamic diameter (measured by a dynamic light scattering (DLS) method) of a hydrophilic composition ranges from 2 nm to 15 nm. If the iron oxide core is small, the ratio of T2 relaxivity(r_2) and T1 relaxivity(r_1) [r_2/r_1] is reduced, thereby execution of positive contrast(T1) is enabled. As shown in Example 10 (*in vitro* MRI test), the hydrophilized iron oxide composition with a small core diameter which are formed by glucose 6-phosphate or glucose 6-phosphate ethanolamine or glucose 6-phosphate polyethyleneglycol show relatively high ' r_1 ' and low ' r_2 ', thus show low r_2/r_1 . A contrast agent containing the above colloids was injected through a tail vein of a rat to execute MRI positive contrast and, as a result, distinct and bright images (positive contrast) were obtained as shown in Examples 7-1, 8-1 and 8-2. Until 1 hour or 2 hours, the blood vessel was brightly contrasted, however after 24 hours, completely lost image brightness for contrasting. From such result, it is presumed that, although the contrast agent resides several hours, it is completely removed from the blood vessel after about 1 day. Accordingly, it can be understood that angiographic imaging is possibly executed using the foregoing contrast agent.

- [82] The present invention also describes colloids and a T2 MRI contrast agent including the colloids. The colloids are prepared by dispersing a composition, which includes hydrophilic iron oxide particle having a monosaccharide-phosphate derivative adhered to the surface, in water, wherein: (i) the monosaccharide-phosphate derivative is glucose 6-phosphate ethanolamine or glucose 6-phosphate polyethyleneglycol; (ii) a size of an iron oxide core ranges from 7 nm to 25 nm; and (iii) a number mean hydrodynamic diameter of a hydrophilic composition (measured by a dynamic light scattering (DLS) method) ranges from 7 nm to 50 nm. The iron oxide core is relatively large, and T2 relaxation rate (r_2) is sharply increased while T1 relaxation rate (r_1) is almost the same. Therefore, r_2/r_1 is significantly increased, in turn negative contrast effects (T2) is increased. As a result, negative contrast (T2) is advantageously executed while positive contrast becomes substantially impossible. As shown in Example 10 (*in vitro* MRI test), the hydrophilized iron oxide composition with a large core diameter which are formed by glucose 6-phosphate ethanolamine or glucose 6-phosphate polyethyleneglycol show relatively low ' r_1 ' and high ' r_2 ', thus show high r_2/r_1 . A contrast agent containing the above colloids was injected through a tail vein of a rat to execute MRI negative contrast and, as a result, strong negative contrast (darkening)

was obtained in lymph nodes after 1 day as shown in Examples 8-3 and 9. From such result, it can be understood that using the foregoing contrast agent may enable imaging of bio-tissues such as lymph nodes with negative contrast (T2).

[83] The colloids including a composition, which includes hydrophilic iron oxide having a monosaccharide-phosphate or a monosaccharide-phosphate derivative adhered to the surface thereof, provided by the present invention, exhibit no or very little toxicity *in vivo*. As shown in Example 11, the result of cytotoxicity test demonstrated that all nanoparticles, that is, (A) 10 nm iron oxide nanoparticles stabilized by glucose 6-phosphate, (B) 10 nm iron oxide nanoparticles stabilized by glucose 6-phosphate-PEG derivatives, and (C) 3 nm iron oxide nanoparticles stabilized by glucose 6-phosphate-aminoalcohol, do not influence cellular viability up to a concentration of 200 ppm, thereby exhibiting superior biocompatibility.

[84] Hereinafter, exemplary embodiments will be described in detail with reference to the accompanying drawings.

[85] [EXAMPLE 1] Composition including iron oxide nanoparticles hydrophilized by glucose 6-phosphate

[86] Dispersion was prepared by dispersing 100 mg of iron oxide (Fe_3O_4) having oleic acid adhered to the surface thereof and a size of 3 nm in 8 ml of tetrahydrofuran (THF). A solution was prepared by dissolving 200 mg of glucose 6-phosphate sodium salt in 2 ml of distilled water (DIW). The dispersion and the solution were mixed. The mixture was agitated and heated at 60°C for 4 hours, followed by settling and cooling the reaction product. The top THF layer was removed, resulting in a composition including hydrophilic iron oxide. Adding DIW to the composition, a colloidal solution was prepared. The colloidal solution was left at room temperature for six (6) months, a change in turbidity was not observed to demonstrate excellent long term stability.

[87] Hydrodynamic diameter of the nanoparticle composition in the colloidal solution was measured using Malvern Zetasizer Nano ZS. The hydrodynamic diameter was about 3.8 nm, which is substantially similar to the core size(3nm). After 6 months, the hydrodynamic diameter was 3.9 nm.

[88] [EXAMPLE 2] Preparation of composition including iron oxide nanoparticles hydrophilized by mannose 6-phosphate

[89] According to the same procedure described in Example 1, 7 nm iron oxide nanoparticles were dispersed in water using mannose 6-phosphate sodium salt. Using Malvern Zetasizer Nano ZS, a hydrodynamic diameter measured to be 8.7 nm, thus demonstrating the size substantially similar to the core size(7nm).

[90] [EXAMPLE 3] Preparation of composition including iron oxide nanoparticles hydrophilized by fructose 6-phosphate

[91] According to the same procedure described in Example 1, 10 nm iron oxide

nanoparticles were dispersed in water using fructose 6-phosphate sodium salt. Using Malvern Zetasizer Nano ZS, a hydrodynamic diameter was measured to be 11.3 nm, thus demonstrating the size substantially similar to the core size(10nm).

[92] [EXAMPLE 4] Synthesis of glucose 6-phosphate polyethyleneglycol

[93] [EXAMPLE 4-1] Synthesis of phosphate-diethylamine

[94] After dissolving 1 g of glucose 6-phosphate sodium salt in 10 ml of 2-(N-morpholino)ethane sulfonic acid (MES) buffer solution, 0.68 g of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and 0.4 g of N-hydroxy succinimide (NHS) are mixed with the solution and maintained for 30 minutes. Then, 0.23 ml of diethylamine was added to the mixture, resulting in glucose 6-phosphosphate-diethylamine.

[95] [EXAMPLE 4-2] Synthesis of glucose 6-phosphate-diethylamine-PEG

[96] After dispersing 17.75 g of methoxy polyethyleneglycol carboxyl (mPEG-COOH, 5000) in 40 ml of MES buffer solution, 1.361 g of EDC and 0.817 g of NHS were added to the dispersion and agitated for 30 minutes. Then, after adding glucose 6-phosphate-diethyl amine synthesized in Example 4-1 to the above solution, the mixture was agitated for 1 day. Following this, unreacted material and a byproduct were removed through dialysis, followed by removal of water.

[97] [EXAMPLE 5] Synthesis of glucose 6-phosphate ethanolamine

[98] After dissolving 1 g of glucose 6-phosphate sodium salt in 10 ml of MES buffer solution, 0.68 g of EDC and 0.4 g of NHS were mixed with the solution and maintained for 30 minutes. Then, 0.22 ml of ethanolamine (2-aminoethanol) was added to the mixture, resulting in glucose 6-phosphate aminoalcohol.

[99] [EXAMPLE 6] Preparation of composition of iron oxide nanoparticles that include glucose 6-phosphate ethanolamine adhered to the surface

[100] Using the glucose 6-phosphate derivatives in Example 4 and 5, nanoparticle compositions were prepared by the same procedure according to Example 1.

[101] [EXAMPLE 7] *In vivo* magnetic resonance imaging experiment with colloidal solution of iron oxide nanoparticles hydrophilized by monosaccharide phosphate

[102] According to the methods proposed in Examples 1, 2 and 3, a composition including iron oxide nanoparticles hydrophilized in water and its colloidal solution were prepared, followed by analysis of a hydrodynamic diameter using a Malvern Zeta sizer Nano ZS device.

[103] For the colloidal solution of iron oxide nanoparticles surface-modified using monosaccharide phosphate and the colloidal solution of iron oxide nanoparticles hydrophilized by the methods described in Comparative Examples 1 and 2, hydrodynamic diameters are listed in Table 1. For the iron oxide nanoparticle surface-modified using monosaccharide phosphate, it was found that a difference between a

core size and a number mean hydrodynamic diameter were much smaller, compared to Comparative Examples 1 and 2.

[104] [TABLE 1]

[105]

Iron oxide core size	Material for hydrophilization	Hydrodynamic diameter (volume mean) (nm)	Hydrodynamic diameter (number mean) (nm)	Difference between number mean hydrodynamic diameter and core size (nm)
2 nm	PO-Glu	4.0	3.2	1.2
3 nm	PO-Glu	6.7	3.8	0.8
4 nm	PO-Glu	6.0	4.7	0.7
7 nm	PO-Glu	9.7	8.0	1.0
10 nm	PO-Glu	23.4	15.3	5.3
20 nm	PO-Glu	38.6	23.0	3.0
2 nm	PO-Man	8.9	7.9	5.9
7 nm	PO-Man	14.4	8.7	1.7
10 nm	PO-Man	20.6	14.1	4.1
2 nm	PO-Fru	6.0	5.2	3.2
7 nm	PO-Fru	18.5	12.5	5.5
10 nm	PO-Fru	23.6	11.3	1.3
10 nm (Comparative Example 1)	PLGA	46	42	32
3 nm (Comparative Example 2)	PO-PEGs	21	15	12

[106] *PO-Glu: Glucose 6-phosphate, PO-Man: Mannose 6-phosphate, PO-Fru: Fructose-6-phosphate

[107] [EXAMPLE 7-1] Magnetic resonance T1 imaging experiment with composition including glucose 6-phosphate-bonded 3 nm core iron oxide nanoparticles

[108] Using a wrist coil in MRI scanner (Trio 3.0T, Siemens), the colloidal solution containing iron oxide nanoparticles dispersed and hydrophilized therein was subjected to evaluation of *in vivo* T1 imaging performance, as shown in Table 1.

[109] The evaluation of *in vivo* T1 imaging performance was executed with rat F-344. The rat weighed 200 to 300 g. After anesthetizing, the rat was placed horizontally in the MRI scanner and cross-sections thereof were observed. MRI images of the rat were taken before, immediately after, 2 hours after and 24 hours after injection of a contrast agent, respectively, in order to observe and compare blood vessels of the rat before and after the injection of the contrast agent. Adding 5% glucose solution (Joong-wea (JW) Pharmaceutical) to the colloidal solution of 3 nm core iron oxide nanoparticles shown in Table 1, the contrast agent was prepared. Iron content was analyzed through ICP-

AES and an administration dose was calculated in consideration of the weight of mouse, to prepare a contrast agent with a total volume of 1 ml. The contrast agent was injected through a tail vein of the rat in an amount of 5.2 mg Fe/kg (rat).

[110] Determination of *in vivo* T1 relaxation performance was executed using 3D SPGR sequence (TR/TE: 25/5.1, Flip angle: 25°), a scan time was 12 minutes, an image thickness was 1 mm, the number of lattices was 256×146 and FOV was 65×110 mm.

[111] In order to quantify T1 contrast imaging effects of the prepared contrast agent, one was selected among cross-sections of the highest visible parts, that is, the aorta, subclavian vein, right atrium and axillary vein, and a bright part thereof was selected as ROI (Region of Interest) in order to measure signal intensity thereof. Since an overall signal intensity of the acquired MRI images is altered whenever it is measured, relative signal intensity (SNR: Signal to Noise Ratio) was determined using saline as a noise. Comparing SNR before and after using the contrast agent, T1 signal enhancement ratio ($\Delta R1$) was calculated and results thereof are illustrated by the graphs in the figure. The following Equation 1 is a method for calculation of T1 signal enhancement ratio ($\Delta R1$).

[112] [Equation 1]

[113] T1 signal enhancement ratio ($\Delta R1$) = $100 \times [1 - (SNR_t / SNR_0)]$

[114] SNR_0 (SNR before administration of contrast agent) = [Signal intensity of ROI₀ / Signal intensity of muscle₀]

[115] SNR_t (SNR after administration of contrast agent) = [Signal intensity of ROI_t / Signal intensity of muscle_t]

[116] Figure 4 is an MRI T1 angiographic image of a rat taken by injecting a contrast agent into a rat, wherein the contrast agent includes colloids formed by dispersing a composition, which includes core iron oxide nanoparticles having a size of 3 nm hydrophilized therein, in water. It can be confirmed the blood vessels of the rat is observed as white highlighted part (positive contrast) and the contrast agent resides *in vivo* for 2 hours or more. For existing gadolinium contrast agent, since *in vivo* retention time is very short such as less than 1 minute, MRI scan time for imaging cannot be extended, thus not acquiring high resolution images. In contrast, the iron oxide contrast agent prepared according to the present invention has a relatively long *in vivo* retention time, thus enabling imaging while elongating the scan time. Therefore, it is confirmed that high resolution images may be obtained and even micro-vascular parts can be observed.

[117] Figure 5 illustrates MR signal intensities and demonstrates that brightness is increased by 4 times at the maximum, compared to before injection of the contrast agent. Moreover, it was confirmed that even the subclavian vein having a size of 0.2 mm can be clearly observed.

[118] [EXAMPLE 8] *In vivo* MRI image formation with contrast agent hydrophilized using glucose 6-phosphate ethanolamine

[119] According to the method proposed in Example 7, iron oxide nanoparticles hydrophilized using glucose 6-phosphate ethanolamine were prepared.

[120] For colloidal solutions of iron oxide nanoparticles surface-modified using a glucose 6-phosphate ethanolamine, hydrodynamic diameters are listed in Table 2.

[121] [TABLE 2]

[122]

Core size	Vol. mean (nm)	No. mean (nm)
3 nm	18	8
10 nm	14	9

[123] [EXAMPLE 8-1] Rat angiographic T1 contrast agent of composition including 3 nm iron oxide hydrophilized using glucose 6-phosphate ethanolamine

[124] Iron oxide nanoparticles having a core size of 3 nm hydrophilized using glucose 6-phosphate ethanolamine were used for T1 angiographic contrast imaging by the same method described in Example 7-1. Results thereof are shown in figure 6.

[125] After treating the above results according to Equation 1 in Example 7-1, results thereof are shown in figure 7. From the figure, it can be seen that signals in the inferior vena cava, right atrium and aorta are noticeably increased.

[126] [EXAMPLE 8-2] Rat angiographic T1 contrast imaging with 7 nm iron oxide hydrophilized using glucose 6-phosphate ethanolamine

[127] Iron oxide nanoparticles having a core size of 7 nm hydrophilized using glucose 6-phosphate ethanolamine were used for T1 angiographic contrast imaging by the same method described in Example 8. Results thereof are shown in figure 8.

[128] After treating the above results according to Equation 1 in Example 7-1, results thereof are shown in figure 9. From the figure, it can be seen that signals in the inferior vena cava, right atrium and aorta are noticeably increased.

[129] [EXAMPLE 8-3] T2 contrast imaging of mouse lymph node with composition including 7 nm iron oxide hydrophilized using glucose 6-phosphate ethanolamine

[130] In order to evaluate applicability of iron oxide nanoparticles having a core size of 7 nm hydrophilized using glucose 6-phosphate aminoalcohol as an MRI contrast agent, *in vivo* T2 relaxation performance was measured using a loop coil in an MRI scanner (Trio 3.0T, Siemens).

[131] Evaluation of *in vivo* relaxation performance was executed with a nude mouse (BALB/c nude mouse) and the mouse weighed about 20 to 30 g. After anesthetizing,

the mouse was placed horizontally in the MRI scanner, followed by observing cross-section thereof. The MRI images of the nude mouse were subjected to measurement before and 24 hours after injecting the contrast agent, and lymph nodes before and after injection of the contrast agent were observed and compared to each other. The contrast agent was dispersed in 0.5 ml of 5% DW and iron content was measured through ICP-AES. Also, the contrast agent was injected through a tail vein of the mouse with an administration dose of 10.4 mg Fe/kg in consideration of the weight of mouse.

- [132] Determination of *in vivo* T2 relaxation performance was conducted using T2Me3d pulse sequences provided by Siemens Co., and particular parameters are as follows.
- [133] TR (repetition time) = 40.0 msec, TE (echo time) = 22.0 msec, FOV = 49 mm x 70 mm, Matrix size = 256 x 180, slice thickness = 0.6 mm, number of acquisition = 6
- [134] In order to quantify T2 attenuation effects of the prepared contrast agent, each cross-section was selected from the highest visible lymph nodes, that is, inguinal lymph node and brachial lymph node and discolored parts thereof were selected as ROI (Region of Interest) in order to measure signal intensity thereof. Since an overall signal intensity of the acquired MRI images is altered whenever it is measured, absolute value of the signal intensity (S) is not proper to evaluate contrast imaging performance. Therefore, for the inguinal lymph node, the right hind leg muscle was used as a control (N: noise). On the other hand, for the brachial lymph node, the right paw muscle was used as a control (N: noise). Compared to the controls, relative signal intensity (SNR: Signal to Noise Ratio) was calculated. By comparing SNR values before and after using the contrast agent, T2 signal attenuation ratio (ΔR_2) was calculated. The results are illustrated by the graphs in figure 11. The following Equation 2 is a method for calculation of T2 signal attenuation ratio (ΔR_2).
- [135] [Equation 2]
- [136] $T2 \text{ signal attenuation ratio } (\Delta R_2) = 100 \times [1 - (SNR_t / SNR_0)]$
- [137] SNR_0 (SNR before administration of contrast agent) = [Signal intensity of ROI₀ / Signal intensity of muscle₀]
- [138] SNR_t (SNR after administration of contrast agent) = [Signal intensity of ROI_t / Signal intensity of muscle_t]
- [139] Figure 10 illustrates *in vivo* MRI lymph node contrast image obtained using nanoparticles of 7 nm iron oxide modified by glucose 6-phosphate ethanolamine derivative. From the figure, it can be seen that a normal lymph node of a mouse had iron oxide uptake 1 day after injection, thus turning dark. Figure 11 shows a decrease in signal intensity according to Equation 2, demonstrating considerable decrease in signal intensity.
- [140] [EXAMPLE 9] *In vivo* MRI image formation with composition including 10 nm core

iron oxide hydrophilized using glucose 6-phosphate polyethyleneglycol

[141] Using monosaccharide-phosphate-polyethyleneglycol prepared by the methods described in Example 4 and 5, 10 nm core iron oxide was hydrophilized to prepare colloids having a number mean hydrodynamic diameter of 30 nm. According to the same procedure described in Example 8-3, T2 contrast imaging performance for mouse lymph nodes was tested, thus obtaining images of the lymph nodes before and after injection of the contrast agent.

[142] For colloidal solutions of iron oxide nanoparticles surface-modified using a glucose 6-phosphate polyethyleneglycol, hydrodynamic diameters are listed in Table 3.

[143] [TABLE 3]

Core size	Vol. mean (nm)	No. mean (nm)
3 nm	19	14
10 nm	96	26

[145] Figure 12 illustrates *in vivo* MRI lymph node contrast image obtained using nanoparticles of 10 nm iron oxide modified by glucose 6-phosphate polyethyleneglycol. From the figure, it can be seen that a normal lymph node had iron oxide uptake 1 day after injection, thus turning dark. Figure 13 shows a decrease in signal intensity according to Equation 2, demonstrating considerable decrease in signals.

[146] [EXAMPLE 10]MR *in vitro* relaxation characteristic of composition including iron oxide nanoparticles surface-modified using monosaccharide phosphate and a derivative thereof

[147] In order to determine MR contrast imaging ability of each of compositions including iron oxide nanoparticles hydrophilized by the methods described in Examples 1, 2 and 3, iron oxide nanoparticles having sizes of 2 nm, 3 nm, 7 nm, 10 nm and 20 nm, respectively, were subjected to phantom imaging using a gradient coil in 4.7 T MR scanner(Biospec 47/40, Bruker Biospin MRI GmbH), in order to evaluate relaxation performance. A concentration of iron oxide nanoparticles was measured through ICP-AES, T2 relaxation time was measured using MSME (Multi Slice-Multi Echo sequence) pulse sequence, and particular parameters are as follows.

[148] T1 imaging parameters are as follows: RARE sequence, TR = 100, 200, 500, 1,000, 2,000, 4,000, 6,000, 8,000 ms, TE = 7,756 ms, FOV = 5 cm, Matrix size = 128×128, slice thickness = 2 mm.

[149] T2 imaging parameters are as follows:

[150] Carr Purcell Meiboom Gill (CPMG) sequence, TR = 10 ms, TE = 7.5 960.0 ms, FOV

= 5 cm, Matrix size = 128×128, slice thickness = 2 mm.

[151] MRI *in vitro* imaging results of iron oxide nanoparticles using a monosaccharide-phosphate are shown in Table 4.

[152] [TABLE 4]

[153]

core diameter	Material for hydrophilization	r1 (mM ⁻¹ s ⁻¹)	r2 (mM ⁻¹ s ⁻¹)	r2/r1
2 nm	PO-Glu	1.3	1.7	1.3
3 nm	PO-Glu	3.5	14.8	4.2
4 nm	PO-Glu	2.8	20.0	7.0
7 nm	PO-Glu	4.3	38.0	8.81
10 nm	PO-Glu	3.3	82.4	24.4
20 nm	PO-Glu	1.8	526	288
7 nm	PO-Man	4.0	68.3	16.8
10 nm	PO-Man	3.6	146	39.9
10 nm	PO-Fru	4.1	127	30.8
3 nm	PO-Glu-EA	3.3	26	7.8
7 nm	PO-Glu-EA	2.5	41	16.4
3 nm	PO-Glu-PEG	3.9	30	7.7
10 nm	PO-Glu-PEG	2.6	130	50.6

[154] *PO-Glu: Glucose 6-phosphate, PO-Man: Mannose 6-phosphate, PO-Fru: Fructose-6-phosphate, PO-Glu-EA: Glucose 6-phosphate ethanolamine derivative, PO-Glu-PEG: Glucose 6-phosphate PEG derivative

[155] Table 4 shows MRI relaxation performance of each of colloidal solutions of iron oxide nanoparticles surface-modified using a monosaccharide-phosphate and/or derivative thereof. Iron oxide nanoparticles having a small core size may be effectively used as a T1 contrast agent, since r1 value is not too small while r2 value is small. On the other hand, iron oxide nanoparticles having a large core size exhibit a much larger r2 value, thus being used as a T2 contrast agent. Accordingly, it was confirmed that iron oxide nanoparticles substituted with a monosaccharide-phosphate and a derivative thereof may be effectively used as T1 and/or T2 contrast agent.

[156] [EXAMPLE 11] Toxicity test of colloidal solution of iron oxide nanoparticles surface-modified using glucose 6-phosphate and derivative thereof

[157] In a toxicity test of iron oxide nanoparticle colloidal solution, MTT assay was conducted with Hep G2 cells. Three kinds of nanoparticles, that is, 10 nm core iron oxide nanoparticles hydrophilized using glucose 6-phosphate (A); 10 nm core iron

oxide nanoparticles hydrophilized using a glucose 6-phosphate-PEG derivative (B); and 3 nm core iron oxide nanoparticles hydrophilized using glucose 6-phosphate-aminoalcohol(C) were dispersed, respectively, in a 5% DW solution. Then, each solution passed through a 0.2 μ m sterile syringe filter. The filtered solution was subjected to measurement of a concentration by inductively coupled plasma-atomic emission spectroscopy (that is, ICP-AES). After measuring the concentration, 200 μ l of fraction taken from each of the iron oxide nanoparticle colloidal solutions and mixed with 200 μ l of a medium (DMEM: Dulbecco's Modified Eagle's Medium 89%, Pluronic® F-127 10%, AA: antibiotic-antimycotic 1%). Thereafter, the solution was diluted by 1/2 times, to prepare a total of nine (9) samples. As a control, 5% DW solution without iron oxide was prepared by the same procedures as described above. 100 μ l of each sample was added to HepG2 cells proliferated by subculture, followed by incubation at 37°C for 24 hours. Next, 20 μ l of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) reagent was added, followed by incubation at 37°C for 4 hours. In order to dissolve formazan crystals generated during incubation, 100 μ l of a soluble solution was added to the above material and incubation was additionally continued at 37°C for 24 hours. After incubation, optical densities at 550 nm and 690 nm, respectively, were measured using a microplate reader (Molecular Devices Co., Spectra Max 190) and cell viability was calculated from the measured optical densities. The cell viability may be calculated according to the following Equation 3.

[158] [Equation 3]

[159] Cell viability (%) = $\{[OD_{i,550} - OD_{i,690}]/[ODS_{i,550} - ODS_{i,690}]\} \times 100$

[160] $OD_{i,550}$: Optical density at 550 nm of well plate No. i in which the sample is introduced.

[161] $OD_{i,690}$: Optical density at 690 nm of well plate No. i in which the sample is introduced.

[162] $ODS_{i,550}$: Optical density at 550 nm of control well plate No. i.

[163] $ODS_{i,690}$: Optical density at 690 nm of control well plate No. i.

[164] [00157] Figure 14 is graphs illustrating results of cell viability tests. In a cell viability test, an acceptable error range (commonly, tolerance) is generally $\pm 20\%$. From results of the present test, it can be found that 80% or more of cell viability was exhibited at a concentration section to be tested. Especially, since cells show no abnormal condition even at a high concentration of 200 μ g/mL, it may be considered that iron oxide nanoparticles have favorable biocompatibility.

[165] [EXAMPLE 12] Preparation of colloidal solution of nanoparticles hydrophilized by glucose 6-phosphate

[166] Several kinds of nanoparticles stabilized with an organic surfactant were hy-

drophilized using glucose 6-phosphate by the same procedure described in Example 1, to prepare a colloidal solution having high dispersion stability. Results thereof are shown in Table 5.

[167] [TABLE 5]

[168]

Core nanoparticle	Size of core nanoparticle (nm)	Hydrodynamic diameter (No. mean) (nm)
MnO	14 nm	20 nm
ZnO	20 nm	25 nm
CdS	6 nm	10 nm
Au	10 nm	15 nm
CoFe ₂ O ₄	12 nm	15 nm
FePt	10 nm	13 nm
GdO	25 nm	30 nm
CdSe/CdS (core shell)	8 nm	12 nm

[169] [EXAMPLE 13]Hydrophilization of nanoparticles using glucose 6-phosphate in various solvents

[170] Various polar solvents such as dimethylsulfoxide (DMSO) and ethanol having affinity to water were used instead of the solvent THF used in Example 1. Using glucose 6-phosphate, iron oxide nanoparticles having a size of 10 nm were hydrophilized, thus resulting in a colloidal solution having dispersion stability in water. Table 6 shows relative ratios of solvents used in hydrophilization experiments and DIW, reaction temperature, reaction time, hydrodynamic diameter after hydrophilization, etc.

[171] [EXAMPLE 13-1] Preparation of nanoparticle colloidal solution by hydrophilization of 10 nm iron oxide nanoparticles using glucose 6-phosphate in DMSO

[172] A dispersion of 100 mg of iron oxide nanoparticles stabilized using oleic acid in 8 ml of DMSO, and another dispersion of 200 mg of glucose 6-phosphate sodium salt in 2 ml of DIW, were admixed and the mixture was agitated and reacted at 120°C for 12 hours, followed by cooling and settling the same. After removal of DMSO, a hydrophilic composition was obtained. Adding distilled water to the composition, a colloidal solution of nanoparticles surface-substituted with glucose 6-phosphate having excellent dispersion stability in water was achieved.

[173] [EXAMPLE 13-2]Hydrophilization of 10 nm iron oxide nanoparticles using glucose 6-phosphate in ethanol

[174] After adding 100 mg of iron oxide nanoparticles stabilized using oleic acid to 8 ml of

ethanol, a solution of 200 mg of glucose 6-phosphate sodium salt dispersed in 2 ml of DIW was mixed with the above nanoparticle solution and the mixture was agitated and reacted at 70°C for 12 hours, followed by cooling and settling the same. After removal of ethanol, a hydrophilized nanoparticle composition was obtained. Adding distilled water to the composition, a colloidal solution of nanoparticles surface-substituted with glucose 6-phosphate having excellent dispersion stability in water was achieved.

[175] [TABLE 6]

[176]

Solvent	Solvent : water	Reaction temperature/time	Hydrodynamic diameter (volume mean, nm)	Hydrodynamic diameter (number mean, nm)
DMSO	8:2	120°C/8h	26.9	11.9
Ethanol	8:2	70°C/8h	48.6	13.05

[177] [EXAMPLE 14]Preparation of iron oxide nanoparticle colloidal solution by glucose 6-phosphate

[178] [EXAMPLE 14-1]Modification of hydrophobic iron oxide nanoparticles to be hydrophilic

[179] According to Example 1 in Korean Patent Application No. 10-2011-0011294, hydrophobic iron oxide was modified to be hydrophilic. 50 mg of iron oxide (Fe_3O_4) with a size of 3 nm and oleic acid adhered on the surface thereof and sodium sulfate (Na_2SO_4 , average particle size: 150 μm) were mixed in a ratio by weight of 1:500. The mixture was agitated in n-hexane and then evaporated hexane. By heating the mixture of iron oxide nanoparticles and sodium sulfate powder at 500°C for 5 hours under atmosphere, oleic acid was removed. In order to remove the salt, the nanoparticles and salt powder were washed three times with distilled water. The product was identified to be hydrophilic by observing iron oxide nanoparticles dispersed in water. The agglomerated particles were not observed after heating. Although the prepared iron oxide nanoparticles are dispersed in water, they tend to settle to the bottom over time since a stabilizer is not present enough on the surface thereof.

[180] As a result of measuring a hydrodynamic diameter of the nanoparticle composition in the colloidal solution using Malvern Zetasizer Nano ZS, it was found that the hydrodynamic diameter is 30 nm and the reason of this is to be considered that particles are agglomerated to one another in an aqueous solution since a surface stabilizer is not present.

[181] [EXAMPLE 14-2]Stabilization of the modified iron oxide nanoparticles using glucose 6-phosphate

[182] 1 g of glucose 6-phosphate sodium salt was added to an aqueous solution (10 ml) of

iron oxide nanoparticles prepared in Example 14-1 and maintained at 60°C for 4 hours under sonication. After completing the reaction, it can be seen that a colloidal solution of iron oxide nanoparticles attached with glucose 6-phosphate were prepared.

Turbidity did not change after leaving for 6 months at room temperature, which demonstrated excellent long term stability of colloids. As a result of measuring a hydrodynamic diameter of the nanoparticle composition in the colloidal solution using Malvern Zetasizer Nano ZS, it was found that the hydrodynamic diameter is 8.5 nm. Therefore, compared to iron oxide nanoparticles prepared in Example 14-1, it can be confirmed that the hydrodynamic diameter is decreased while having improved dispersion stability.

[183] [COMPARATIVE EXAMPLE 1] Preparation of hydrophilized capsule of iron oxide nanoparticles

[184] 40 mg of iron oxide nanoparticles having a size of 10 nm stabilized with oleic acid, as well as 40 mg of poly(lactic-co-glycolic acid)(PLGA), were dispersed in an ethyl acetate solution. Then, the dispersion was mixed with 4 ml of Pluronic® F127 solution (BASF Corporation, difunctional block copolymer), followed by agitation, resulting in capsules. Measuring results of a hydrodynamic diameter of the capsules are shown in Table 1.

[185] [COMPARATIVE EXAMPLE 2] Hydrophilization of iron oxide nanoparticles using PO-PEGs

[186] 50 mg of iron oxide nanoparticles having a size of 3 nm stabilized with oleic acid, as well as 5 g of PO-PEGs (PEG, MW: 2000), were provided in 10 ml of ethanol, followed by agitation at 70°C for 12 hours, resulting in hydrophilic iron oxide nanoparticles. Measuring results of a hydrodynamic diameter of the nanoparticles are shown in Table 1.

[187] As set forth above, specific technical configurations and embodiments of the present invention have been described according to the foregoing examples and accompanying drawings, however, such examples are provided for illustrative purpose to more clearly understand the present invention and the scope of the present invention is not particularly limited thereto. Therefore, it will be apparent to those skilled in the art that various modifications and alterations can be made from the foregoing description.

[188] Accordingly, the spirit of the present invention is not particularly restricted to the exemplary embodiments described above and the scope of the present invention may include not only the subject matters defined by the appended claims but also modification and equivalents thereof.

Claims

- [Claim 1] Hydrophilic nanoparticles surface-modified by adhering a monosaccharide-phosphate or a monosaccharide-phosphate derivative on the surface of inorganic particles.
- [Claim 2] The nanoparticles of claim 1, wherein a number mean of hydrodynamic diameter of the surface-modified hydrophilic nanoparticle ranges from 1 nm to 200 nm and a difference between a number mean hydrodynamic diameter and a core size of inorganic particle is 6 nm or less.
- [Claim 3] The nanoparticles of claim 1, wherein the inorganic particle is one or two or more selected from a group consisting of metal, metal chalcogenide, metal oxide, magnetic materials, magnetic alloys, semiconductor materials and multi-component hybrid structures.
- [Claim 4] The nanoparticles of claim 1, wherein the monosaccharide-phosphate includes one or two or more selected from a group consisting of glucose-6-phosphate, fructose-6-phosphate and mannose-6-phosphate.
- [Claim 5] The nanoparticles of claim 1, wherein the monosaccharide-phosphate derivative comprises monosaccharide-phosphate having aminoalcohol bonded to a phosphate group thereof.
- [Claim 6] The nanoparticles of claim 5, wherein the aminoalcohol is one or two or more selected from a group consisting of ethanolamine, heptaminol, isoetharine, norepinephrine, propanolamine and sphingosine.
- [Claim 7] The nanoparticles of claim 1, wherein the monosaccharide-phosphate derivative comprises monosaccharide-phosphate having polyethyleneglycol bonded to a phosphate group thereof.
- [Claim 8] The nanoparticles of claim 7, wherein the polyethyleneglycol has amine groups at one end or both ends thereof, and a number mean molecular weight ranging from 300 to 50,000.
- [Claim 9] The nanoparticles of claim 3, wherein the metal is one or two or more selected from a group consisting of Pd, Pt, Au, Cu and Ag; the metal chalcogenide is $MxEy$,
[wherein M is Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zr, Mo, Ru, Rh, Ag, W, Re, Ta, Hf or Zn;
E = O, S or Se;
x ranges from 1 to 3; and
y ranges from 1 to 5];
the metal oxide is one or two or more selected from a group consisting

of titanium oxide, vanadium oxide, chromium oxide, manganese oxide, iron oxide, cobalt oxide, nickel oxide, copper oxide, zirconium oxide, molybdenum oxide, ruthenium oxide, rhodium oxide, silver oxide, tungsten oxide, rhenium oxide, tantalum oxide, hafnium oxide and zinc oxide;

the magnetic material is one or two or more selected from a group consisting of Co, Mn, Fe, Ni, Gd, $MM'2O4$ and $MxOy$,

[wherein, in $MM'2O4$ and $MxOy$, M or M' is Co, Fe, Ni, Mn, Zn, Gd or Cr;

x ranges from 1 to 3; and

y ranges from 1 to 5];

the metal alloy is one or two or more selected from a group consisting of CoCu, CoPt, FePt, CoSm, NiFe and NiFeCo; and

the semiconductor material is one or two or more selected from a group consisting of: a material comprising of elements selected from Groups 2 and 6, respectively; a material comprising of elements selected from Groups 3 and 5, respectively; a material comprising of Group 4 element; a material comprising of elements selected from Groups 4 and 6, respectively; and a material comprising of elements selected from Groups 5 and 6, respectively.

[Claim 10] The nanoparticles of claim 3, wherein the multi-component hybrid structure is a core-shell or heterojunction structure.

[Claim 11] The nanoparticles of claim 9, wherein the metal oxide is iron oxide.

[Claim 12] The nanoparticles of claim 11, wherein the iron oxide is one or two or more selected from a group consisting of FeO, Fe_3O_4 (magnetite), $\alpha-Fe_2O_3$, $\beta-Fe_2O_3$, $\gamma-Fe_2O_3$ (maghemite), $\epsilon-Fe_2O_3$, $Fe(OH)_2$, $Fe(OH)_3$, $\alpha-FeOOH$, $\beta-FeOOH$, $\gamma-FeOOH$, $\delta-FeOOH$, $Fe_5HO_8 \cdot 4H_2O$, $5Fe_2O_3 \cdot 9H_2O$, $FeOOH \cdot 4H_2O$, $Fe_8O_8(OH)_6(SO) \cdot nH_2O$, $Fe^{3+}_{16}O_{16}(OH \cdot SO_4)_{12-13} \cdot 10-12H_2O$ and a mixture of Fe_3O_4 (magnetite) and $\gamma-Fe_2O_3$ (maghemite).

[Claim 13] The nanoparticles of claim 11, wherein the iron oxide is one or two or more selected from a group consisting of Fe_3O_4 (magnetite), $\gamma-Fe_2O_3$ (maghemite) and a mixture thereof.

[Claim 14] The nanoparticles of claim 1, wherein the surface-modified hydrophilic nanoparticles are obtained by contacting a solution of a monosaccharide-phosphate or a monosaccharide-phosphate derivative dispersed in water with nanoparticles and a polar solvent, to modify the surface of the nanoparticles into a hydrophilic state.


[Claim 15] A colloidal solution prepared by dispersing the nanoparticles of claim 1

- in water.
- [Claim 16] A contrast agent including the colloidal solution of claim 15.
- [Claim 17] The contrast agent of claim 16, wherein the contrast agent is a magnetic resonance imaging (MRI) T1 contrast agent or T2 contrast agent.
- [Claim 18] An imaging method including *in vivo* injection of the contrast agent of claim 16 or 17.
- [Claim 19] The imaging method of claim 18, wherein the method comprises imaging blood vessels with the MRI T1 contrast agent.
- [Claim 20] The imaging method of claim 18, wherein the method comprises imaging lymph nodes with the MRI T2 contrast agent.
- [Claim 21] A method for manufacturing surface-modified hydrophilic nanoparticles, comprising contacting: a solution of a monosaccharide-phosphate or a monosaccharide-phosphate derivative dispersed in water; a polar organic solvent; and nanoparticles, which are one or two or more selected from a group consisting of metal, metal chalcogenide, metal oxide, magnetic materials, magnetic alloys, semiconductor materials and multi-component hybrid structures, to modify the surface of the nanoparticles into a hydrophilic state.
- [Claim 22] The method of claim 21, wherein the metal oxide is one or two or more selected from a group consisting of Fe_3O_4 (magnetite), $\gamma\text{-Fe}_2\text{O}_3$ (maghemite) and a mixture thereof.
- [Claim 23] The method of claim 21 or 22, wherein a difference between a number mean hydrodynamic diameter of the nanoparticles and a size of Fe_3O_4 (magnetite) and $\gamma\text{-Fe}_2\text{O}_3$ (maghemite) core particles is 6 nm or less.


1/7

【DRAWINGS】

【Figure 1】




【Figure 2】



2/7

【Figure 3】




1: Glucose 6 phosphate-3nm : 3.8nm

2: Mannose 6 phosphate-7nm: 8.7nm


3: Fructose 6 phosphate-10nm : 11.3nm

【Figure 4】




3/7

【Figure 5】




【Figure 6】




4/7

【Figure 7】




【Figure 8】




5/7

【Figure 9】




【Figure 10】




6/7

【Figure 11】




【Figure 12】




7/7

【Figure 13】



【Figure 14】

MTT assay_Hep G2



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR2012/006206**A. CLASSIFICATION OF SUBJECT MATTER****A61K 9/16(2006.01)i, A61K 47/48(2006.01)i, A61K 47/30(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K 9/16; A61K 49/06; B82B 3/00; B82Y 5/00; A61B 5/055; A61K 9/50; C01G 9/02; A61K 47/48

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: nanoparticle, iron oxide, monosaccharide, glucose-6-phosphate, polyethylene glycol, MRI, contrast agent

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2009-136763 A2 (YONSEI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION) 12 November 2009 See the whole document.	1-17,21-23
A	US 2011-0165086 A1 (C. LEE et al.) 07 July 2011 See the whole document.	1-17,21-23
A	US 2010-0143263 A1 (J. CHEON et al.) 10 June 2010 See the whole document.	1-17,21-23
A	US 2004-0253181 A1 (M. PORT et al.) 16 December 2004 See the whole document.	1-17,21-23
A	US 2009-0324494 A1 (S.-J. HAM et al.) 31 December 2009 See the whole document.	1-17,21-23
A	KR 10-2010-0038583 A (KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION) 15 April 2010 See the whole document.	1-17,21-23

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

05 DECEMBER 2012 (05.12.2012)

Date of mailing of the international search report

06 DECEMBER 2012 (06.12.2012)

Name and mailing address of the ISA/KR


Korean Intellectual Property Office
189 Cheongsu-ro, Seo-gu, Daejeon Metropolitan
City, 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, SUN HWA

Telephone No. 82-42-481-5606



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2012/006206

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	H. B. NA, et. al., "Versatile PEG-derivatized phosphine oxide ligands for water-dispersible metal oxide nanocrystals", Chemical Communications, pp. 5167-5169, 2007 See the whole document.	1-17,21-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR2012/006206**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18-20
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 18-20 are directed to a diagnostic method under Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2012/006206

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009-136763 A2	12.11.2009	KR 10-1081445 B1 KR 10-2009-0117648 A WO 2009-136763 A3	08.11.2011 12.11.2009 11.02.2010
US 2011-0165086 A1	07.07.2011	KR 10-1126726 B1 KR 10-2011-0080781 A	29.03.2012 13.07.2011
US 2010-0143263 A1	10.06.2010	CN 101547706 A EP 2131870 A1 EP 2131870 A4 JP 2010-505763 A JP 2010-505763 T KR 10-1043251 B1 KR 10-2008-0092870 A WO 2008-127031 A1	30.09.2009 16.12.2009 03.08.2011 25.02.2010 25.02.2010 21.06.2011 16.10.2008 23.10.2008
US 2004-0253181 A1	16.12.2004	AT 423575 T AU 2003-299388 A1 AU 2003-299388 A8 BR 0316886 A CA 2510531 A1 CN 1744920 A CN 1744920 C0 DE 60326383 D1 DK 1572246 T3 EP 1572246 A2 EP 1572246 B1 ES 2321709 T3 FR 2848850 A1 FR 2848850 B1 JP 04-638738 B2 JP 2006-513198 A JP 2006-513198 T JP 4638738 B2 PT 1572246 E US 2010-0297025 A1 US 7780953 B2 WO 2004-058275 A2 WO 2004-058275 A3	15.03.2009 22.07.2004 22.07.2004 25.10.2005 15.07.2004 08.03.2006 02.01.2008 09.04.2009 08.06.2009 14.09.2005 25.02.2009 10.06.2009 25.06.2004 24.06.2005 03.12.2010 20.04.2006 20.04.2006 23.02.2011 22.05.2009 25.11.2010 24.08.2010 15.07.2004 09.12.2004
US 2009-0324494 A1	31.12.2009	EP 1988928 A1 EP 1988928 A4 JP 2009-531296 A JP 2009-531296 T KR 10-0819377 B1 KR 10-0819378 B1 KR 10-0848930 B1 KR 10-0848931 B1 KR 10-0848932 B1	12.11.2008 16.11.2011 03.09.2009 03.09.2009 04.04.2008 04.04.2008 29.07.2008 29.07.2008 29.07.2008

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2012/006206

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		KR 10-2007-0088388 A	29.08.2007
		KR 10-2007-0088390 A	29.08.2007
		KR 10-2007-0088391 A	29.08.2007
		KR 10-2007-0088392 A	29.08.2007
		KR 10-2007-0088393 A	29.08.2007
		WO 2007-097593 A1	30.08.2007
KR 10-2010-0038583 A	15.04.2010	KR 10-1136190 B	17.04.2012